Trial Profile
A 12-Week, Double-Blind, Placebo Controlled, Parallel Group Study to Assess the Efficacy and Safety of Ropinirole in Patients Suffering From Restless Legs Syndrome (RLS).
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Sep 2023
Price :
$35
*
At a glance
- Drugs Ropinirole (Primary)
- Indications Restless legs syndrome
- Focus Registrational; Therapeutic Use
- Acronyms TREAT-RLS-US
- Sponsors GlaxoSmithKline; GSK
- 28 Nov 2006 New trial record.